WHO says two Bundibugyo vaccine candidates expected to begin testing next week
WHO (17 Nov 2026) expects two Bundibugyo vaccine candidates to begin testing next week; details pending.
By Chronos Editorial Desk · AI-assisted
- Urgency
- L3
- 68
- 80
- 50
- 40
- 80
At a glance
WHO Director-General said "we expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week." The statement is an expectation reported by WHO and does not itself constitute trial registration or sponsor confirmation. Further confirmation is needed from trial registries, sponsors, or national regulators. The remark was published by WHO on 17 November 2026.
- WHO (17 Nov 2026) expects two Bundibugyo vaccine candidates to begin testing next week; details pending.

CHRONOS Wire · November 18 · Alert 6
What happened
The World Health Organization said two vaccine candidates for the Bundibugyo virus are expected to begin testing next week. This is a public expectation from WHO and requires confirmation from trial sponsors or registries.
Why it matters
The expected start is imminent and may be confirmed or amended within days, so follow-up confirmation is likely soon.
CHRONOS Bottom Line
WHO stated an expectation that two Bundibugyo-specific vaccine candidates will begin testing imminently, based on the Director-General's remarks on 17 November 2026. This is an expectation reported by WHO and not itself trial registration or sponsor confirmation.
Full detail
What changed
WHO Director-General publicly stated that two candidate vaccines developed specifically for Bundibugyo virus are expected to begin testing as early as next week, per WHO remarks on 17 November 2026.
What is genuinely new
The WHO Director-General stated on 17 November 2026 that two candidate vaccines developed specifically for Bundibugyo virus are expected to begin testing as early as next week.
Detailed analysis
The WHO Director-General publicly reported an expectation that two vaccine candidates developed specifically for Bundibugyo virus will begin testing as early as next week. The statement should be treated as a forward-looking expectation; it is not itself documentation of trial start, registration, or approvals. Monitoring for registration entries, sponsor statements, and regulator notifications over the coming days is required to confirm whether testing begins as expected.
U.S. Impact
U.S. Impact assessment pending.